Form 4: NeuroPace Chief Medical Officer Sells Shares Under 10b5-1 Trading Plan

NeuroPace's Chief Medical Officer, Martha Morrell, sold a total of 300 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Martha Morrell, the Chief Medical Officer of NeuroPace Inc, executed two transactions involving the sale of company stock.
• On January 29, 2025, she sold 100 shares of common stock at a price of $15 per share.
• On January 30, 2025, she sold an additional 200 shares of common stock, also at $15 per share.
• These sales were conducted under a pre-established Rule 10b5-1 trading plan.
• Following these transactions, Ms. Morrell's direct holdings decreased to 86,762 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing for stock sales by an executive under a pre-arranged plan. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

Sales by company officers are a common occurrence and are often pre-planned under Rule 10b5-1 to avoid accusations of insider trading. This is a routine filing and does not indicate any specific change in the company's outlook.

Comparison to Industry Standards

• Sales by executives under 10b5-1 plans are a common practice across the industry, including companies like Medtronic and Boston Scientific.
• The volume of shares sold is relatively small compared to the total outstanding shares of NeuroPace, and is not unusual for executive transactions.

Stakeholder Impact

• The stock sales by the Chief Medical Officer may have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or financial health.

Key Dates

Keywords

NeuroPace, insider trading, stock sale, Rule 10b5-1, Martha Morrell, NPCE, Chief Medical Officer